S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
What to Expect from the Markets in a Recession
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
What to Expect from the Markets in a Recession
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
What to Expect from the Markets in a Recession
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
What to Expect from the Markets in a Recession
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
OTCMKTS:ABLYF

Ablynx - ABLYF Stock Forecast, Price & News

$50.63
-2.67 (-5.01%)
(As of 05/24/2018)
Add
Compare
Today's Range
$50.63
$50.63
50-Day Range
$50.63
$50.63
52-Week Range
$12.50
$55.04
Volume
100 shs
Average Volume
5,063 shs
Market Capitalization
$3.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ABLYF stock logo

About Ablynx (OTCMKTS:ABLYF) Stock

Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

Receive ABLYF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ablynx and its competitors with MarketBeat's FREE daily newsletter.

ABLYF Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive ABLYF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ablynx and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ABLYF
Previous Symbol
NASDAQ:ABLYF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$62.73 million
Book Value
$2.71 per share

Miscellaneous

Free Float
N/A
Market Cap
$3.81 billion
Optionable
Not Optionable
Beta
1.99

Key Executives

  • Dr. Edwin Moses (Age 64)
    Chief Exec. Officer and Director
  • Mr. Wim Ottevaere (Age 62)
    Chief Financial Officer
  • Mr. Piet Houwen
    Chief Operations Officer
  • Dr. Robert Friesen Ph.D.
    Chief Scientific Officer
  • Lies Vanneste
    Director of Investor Relations













ABLYF Stock - Frequently Asked Questions

How has Ablynx's stock price performed in 2022?

Ablynx's stock was trading at $50.63 on January 1st, 2022. Since then, ABLYF shares have increased by 0.0% and is now trading at $50.63.
View the best growth stocks for 2022 here
.

What is Ablynx's stock symbol?

Ablynx trades on the OTCMKTS under the ticker symbol "ABLYF."

How do I buy shares of Ablynx?

Shares of ABLYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ablynx's stock price today?

One share of ABLYF stock can currently be purchased for approximately $50.63.

How much money does Ablynx make?

Ablynx (OTCMKTS:ABLYF) has a market capitalization of $3.81 billion and generates $62.73 million in revenue each year.

How can I contact Ablynx?

Ablynx's mailing address is TECHNOLOGIEPARK 21 ZWIJNAARDE, GHENT C9, 9052. The official website for Ablynx is www.ablynx.com. The company can be reached via phone at 329-262-0000.

This page (OTCMKTS:ABLYF) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.